Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Massimo Volpe is active.

Publication


Featured researches published by Massimo Volpe.


Journal of Hypertension | 2002

Nitric-oxide-mediated relaxations in salt-induced hypertension: Effect of chronic β1-selective receptor blockade

Francesco Cosentino; Sandro Bonetti; Rudolf Rehorik; Masato Eto; Gabriele Werner‐Felmayer; Massimo Volpe; Thomas F. Lüscher

Background Nebivolol is a new β1-selective adrenergic receptor antagonist with a direct vasorelaxant effect that involves activation of the l-arginine–nitric oxide (NO) pathway. Therefore, treatment with nebivolol may protect against endothelial injury in hypertension. Objective To investigate whether chronic selective β1-blockade with nebivolol could prevent endothelial dysfunction in salt-induced hypertension, and to compare it with atenolol. Methods Dahl salt-sensitive rats were treated for 8 weeks with standard chow or chow containing 4% NaCl alone or in combination with nebivolol (10 mg/kg per day) or atenolol (100 mg/kg per day). Isometric tension was continuously recorded in isolated aorta and small mesenteric arteries. Constitutive NO synthase (cNOS) activity was determined by [3H]citrulline assay. Results Chronic salt administration increased systolic blood pressure by 38 ± 5 mmHg in salt-treated rats as compared with that in control rats. Both nebivolol and atenolol prevented a salt-induced increase in pressure. cNOS activity was significantly decreased by a high-salt diet. The impairment of endothelium-dependent relaxations in response to acetylcholine in salt-treated rats was prevented only by nebivolol, in both large and small arteries. In contrast, the reduced endothelium-independent relaxations and contractions in response to sodium nitroprusside and endothelin-1, respectively, were restored by both drugs. Nebivolol, but not atenolol, restored cNOS activity. Conclusions Despite nebivolol and atenolol having the same blood-pressure-decreasing effect, only nebivolol was able to prevent endothelial dysfunction. This study demonstrates for the first time that the acute NO-mediated vasodilatory action of nebivolol is also present during chronic treatment. Hence, nebivolol might become a new therapeutic tool with which to exert vascular protective effects against end-organ damage in conditions associated with NO deficiency.


Ipertensione e Prevenzione Cardiovascolare | 2013

Strategie per migliorare il controllo della pressione arteriosa in Italia: dalla stratificazione del rischio cardiovascolare globale alla terapia di combinazione

Massimo Volpe; Ettore Ambrosioni; Claudio Borghi; Santina Cottone; Cesare Cuspidi; Nicola De Luca; Francesco Fallo; Claudio Ferri; Alberto Morganti; Maria Lorenza Muiesan; Riccardo Sarzani; Leonardo Sechi; Agostino Virdis; Giuliano Tocci; B. Trimarco; Alessandro Filippi; Giuseppe Mancia


Archive | 2018

Co-morbidity (HFrEF and HFpEF): hypertension

Francesco Paneni; Massimo Volpe


Archive | 2014

EMERGING ANTIHYPERTENSIVE DRUGS

Massimo Volpe; Giuliano Tocci


Ipertensione e Prevenzione Cardiovascolare | 2014

Centri per la diagnosi e la cura dell’ipertensione arteriosa in Italia: distribuzione geografica, caratteristiche cliniche e dotazione strumentale

Giuliano Tocci; Nicola De Luca; Riccardo Sarzani; Ettore Ambrosioni; Claudio Borghi; Santina Cottone; Cesare Cuspidi; Francesco Fallo; Claudio Ferri; Alberto Morganti; Maria Lorenza Muiesan; Leonardo Sechi; Agostino Virdis; Giuseppe Mancia; Massimo Volpe


Archive | 2013

heart failure Tumor necrosis factor-alpha as trigger of platelet activation in patients with

Silvia Riondino; Susanna Grego; Massimo Volpe; Francesco Violi; Pasquale Pignatelli; Luisa Lenti; Giuliano Tocci; Alessandra Brunelli


Archive | 2013

Hyperglycemic Memory Bringing All the Strands Together

Francesco Paneni; Massimo Volpe; Thomas F. Lüscher; Francesco Cosentino


American Heart Association (AHA) 2013 Scientific Sessions | 2013

Epigenetic remodeling of Nox2 by acetyltransferase Gcn5 drives hyperglycemia-induced endothelial oxidative stress

Massimo Volpe; Francesco Cosentino; Thomas F. Lüscher; Lorenzo Castello; Sergio Chiandotto; Sarah Costantino; Francesco Paneni; Rodolfo Battista; Giuliana Capretti


American Heart Association (AHA) 2013 Scientific Sessions | 2013

Targeting Prolyl-isomerase-1 protects against hyperglycemia-induced endothelial dysfunction and vascular inflammation: alterations in patients with type 2 diabetes

Massimo Volpe; Lorenzo Castello; Sergio Chiandotto; Francesco Cosentino; Francesco Paneni; Sarah Costantino; Thomas F. Lüscher; Rodolfo Battista; Giuliana Capretti


Archive | 2012

Triple combination therapy to improve blood pressure control: experience with olmesartan--

Giuliano Tocci; Francesco Paneni; Jasmine Passerini; Massimo Volpe

Collaboration


Dive into the Massimo Volpe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giuliana Capretti

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Giuliano Tocci

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Francesco Cosentino

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giovanna Petrucci

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Francesco Cosentino

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge